496 related articles for article (PubMed ID: 19903491)
1. Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies.
Kreindler JL
Pharmacol Ther; 2010 Feb; 125(2):219-29. PubMed ID: 19903491
[TBL] [Abstract][Full Text] [Related]
2. What's new in cystic fibrosis? From treating symptoms to correction of the basic defect.
Proesmans M; Vermeulen F; De Boeck K
Eur J Pediatr; 2008 Aug; 167(8):839-49. PubMed ID: 18389279
[TBL] [Abstract][Full Text] [Related]
3. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
4. Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.
Mall MA; Mayer-Hamblett N; Rowe SM
Am J Respir Crit Care Med; 2020 May; 201(10):1193-1208. PubMed ID: 31860331
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Root Cause of Cystic Fibrosis.
Trescott L; Holcomb J; Spellmon N; Mcleod C; Aljehane L; Sun F; Li C; Yang Z
Curr Drug Targets; 2015; 16(9):933-44. PubMed ID: 25316272
[TBL] [Abstract][Full Text] [Related]
6. [Physiopathology of cystic fibrosis lung disease].
Chinet T
Rev Mal Respir; 1999 Jun; 16(3):339-45. PubMed ID: 10472642
[TBL] [Abstract][Full Text] [Related]
7. The Evolution of Cystic Fibrosis Care.
Pittman JE; Ferkol TW
Chest; 2015 Aug; 148(2):533-542. PubMed ID: 25764168
[TBL] [Abstract][Full Text] [Related]
8. Treating the Airway Consequences of Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction.
Toprak D; Davis C; Rosenfeld M
Semin Respir Crit Care Med; 2019 Dec; 40(6):751-761. PubMed ID: 31659732
[TBL] [Abstract][Full Text] [Related]
9. Ion channels as targets to treat cystic fibrosis lung disease.
Martin SL; Saint-Criq V; Hwang TC; Csanády L
J Cyst Fibros; 2018 Mar; 17(2S):S22-S27. PubMed ID: 29102290
[TBL] [Abstract][Full Text] [Related]
10. Emerging drug treatments for cystic fibrosis.
Zeitlin PL
Expert Opin Emerg Drugs; 2003 Nov; 8(2):523-35. PubMed ID: 14662004
[TBL] [Abstract][Full Text] [Related]
11. Cystic fibrosis: a review of pulmonary and nutritional therapies.
Amin R; Ratjen F
Adv Pediatr; 2008; 55():99-121. PubMed ID: 19048729
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy for cystic fibrosis: cystic fibrosis transmembrane conductance regulator mutation-specific pharmacologic strategies.
Rubenstein RC
Mol Diagn Ther; 2006; 10(5):293-301. PubMed ID: 17022692
[TBL] [Abstract][Full Text] [Related]
13. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
[TBL] [Abstract][Full Text] [Related]
14. New Therapies to Correct the Cystic Fibrosis Basic Defect.
Bergeron C; Cantin AM
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34201249
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics.
Kunzelmann K; Mall M
Am J Respir Med; 2003; 2(4):299-309. PubMed ID: 14719996
[TBL] [Abstract][Full Text] [Related]
16. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
17. A new era of personalized medicine for cystic fibrosis - at last!
Quon BS; Wilcox PG
Can Respir J; 2015; 22(5):257-60. PubMed ID: 26083544
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy in cystic fibrosis.
Armstrong DK; Cunningham S; Davies JC; Alton EW
Arch Dis Child; 2014 May; 99(5):465-8. PubMed ID: 24464978
[TBL] [Abstract][Full Text] [Related]
19. Emerging drugs for cystic fibrosis.
Amin R; Ratjen F
Expert Opin Emerg Drugs; 2014 Mar; 19(1):143-55. PubMed ID: 24479826
[TBL] [Abstract][Full Text] [Related]
20. [CFTR and transepithelial ionic transport abnormalities in cystic fibrosis].
Becq F
Arch Pediatr; 2003 Sep; 10 Suppl 2():325s-332s. PubMed ID: 14671929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
